The safety of zoledronic acid

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

Zoledronic acid has been marketed for the past 5 years for the treatment of hypercalcemia of malignancy and malignant bone disease in patients with multiple myeloma or a broad range of solid tumors. The safety profile of zoledronic acid in this patient population is well established from the data-bases of several large, randomized, Phase III trials and postmarketing clinical experience. Zoledronic acid is well tolerated, with predictable side effects, primarily transient flu-like symptoms, which are manageable with standard treatment. Renal monitoring is recommended, with dose reductions for patients with renal dysfunction. Monitoring for electrolyte imbalance is also important as is calcium and vitamin D supplementation. ocular complications are rare, and osteonecrosis of the jaw is uncommon and might be avoidable with appropriate dental care.

Original languageEnglish (US)
Pages (from-to)305-313
Number of pages9
JournalExpert Opinion on Drug Safety
Volume6
Issue number3
DOIs
StatePublished - May 1 2007

Fingerprint

zoledronic acid
Safety
Kidney
Phase III Clinical Trials
Osteonecrosis
Dental Care
Bone Diseases
Hypercalcemia
Jaw
Multiple Myeloma
Vitamin D
Electrolytes
Neoplasms
Databases
Calcium
Therapeutics
Population

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

@article{1dc3d72927584fceb20a687c8519177a,
title = "The safety of zoledronic acid",
abstract = "Zoledronic acid has been marketed for the past 5 years for the treatment of hypercalcemia of malignancy and malignant bone disease in patients with multiple myeloma or a broad range of solid tumors. The safety profile of zoledronic acid in this patient population is well established from the data-bases of several large, randomized, Phase III trials and postmarketing clinical experience. Zoledronic acid is well tolerated, with predictable side effects, primarily transient flu-like symptoms, which are manageable with standard treatment. Renal monitoring is recommended, with dose reductions for patients with renal dysfunction. Monitoring for electrolyte imbalance is also important as is calcium and vitamin D supplementation. ocular complications are rare, and osteonecrosis of the jaw is uncommon and might be avoidable with appropriate dental care.",
author = "Allan Lipton",
year = "2007",
month = "5",
day = "1",
doi = "10.1517/14740338.6.3.305",
language = "English (US)",
volume = "6",
pages = "305--313",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "3",

}

The safety of zoledronic acid. / Lipton, Allan.

In: Expert Opinion on Drug Safety, Vol. 6, No. 3, 01.05.2007, p. 305-313.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The safety of zoledronic acid

AU - Lipton, Allan

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Zoledronic acid has been marketed for the past 5 years for the treatment of hypercalcemia of malignancy and malignant bone disease in patients with multiple myeloma or a broad range of solid tumors. The safety profile of zoledronic acid in this patient population is well established from the data-bases of several large, randomized, Phase III trials and postmarketing clinical experience. Zoledronic acid is well tolerated, with predictable side effects, primarily transient flu-like symptoms, which are manageable with standard treatment. Renal monitoring is recommended, with dose reductions for patients with renal dysfunction. Monitoring for electrolyte imbalance is also important as is calcium and vitamin D supplementation. ocular complications are rare, and osteonecrosis of the jaw is uncommon and might be avoidable with appropriate dental care.

AB - Zoledronic acid has been marketed for the past 5 years for the treatment of hypercalcemia of malignancy and malignant bone disease in patients with multiple myeloma or a broad range of solid tumors. The safety profile of zoledronic acid in this patient population is well established from the data-bases of several large, randomized, Phase III trials and postmarketing clinical experience. Zoledronic acid is well tolerated, with predictable side effects, primarily transient flu-like symptoms, which are manageable with standard treatment. Renal monitoring is recommended, with dose reductions for patients with renal dysfunction. Monitoring for electrolyte imbalance is also important as is calcium and vitamin D supplementation. ocular complications are rare, and osteonecrosis of the jaw is uncommon and might be avoidable with appropriate dental care.

UR - http://www.scopus.com/inward/record.url?scp=34248571550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248571550&partnerID=8YFLogxK

U2 - 10.1517/14740338.6.3.305

DO - 10.1517/14740338.6.3.305

M3 - Review article

C2 - 17480179

AN - SCOPUS:34248571550

VL - 6

SP - 305

EP - 313

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 3

ER -